Rapid fluoroquinolone resistance detection in *Pseudomonas aeruginosa* using mismatch amplification mutation assay-based real-time PCR

Danielle E. Madden[1,2,3], Kate L. McCarthy[4,5], Scott C. Bell[6,7,8], Olusola Olagoke[1,2,3], Timothy Baird[2,9], Jane Neill[9], Kay A. Ramsay[8], Timothy J. Kidd[10,11], Adam G. Stewart[5,12], Shradha Subedi[3,12], Keat Choong[3,12], Tamieka A. Fraser[1,2], Derek S. Sarovich[1,2,3*], and Erin P. Price[1,2,3*]

[1]GeneCology Research Centre, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
[2]Sunshine Coast Health Institute, Birtinya, Queensland, Australia
[3]Infection Research Network Sunshine Coast, Birtinya, Queensland, Australia
[4]Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
[5]University of Queensland Centre for Clinical Research, Herston, Queensland, Australia
[6]Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia
[7]Translational Research Institute, Woolloongabba, Queensland, Australia
[8]Child Health Research Centre, The University of Queensland, Centre for Children's Health Research, South Brisbane, QLD, Australia
[9]Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia
[10]School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia
[11]Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
[12]Infectious Diseases Unit, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

Keywords: Antibiotic, AMR, fluoroquinolone, ciprofloxacin, *Pseudomonas aeruginosa*, real-time PCR, SYBR-MAMA

Running title: Rapid FQ resistance detection in *P. aeruginosa*

*Authors contributed equally

Corresponding author: Erin Price, eprice@usc.edu.au Ph: +61 7 5456 5568

Abstract

Antimicrobial resistance (AMR) is an ever-increasing global health concern. Here, we developed two SYBR Green-based mismatch amplification mutation assays (SYBR-MAMAs) targeting GyrA T83I, D87N, D87Y, and D87H, the predominant causes of fluoroquinolone AMR in *Pseudomonas aeruginosa*. SYBR-MAMAs were tested on 85 isolates, 45 with intermediate/full ciprofloxacin resistance. Assays identified the correct phenotype in 84% intermediate/full resistant and 100% sensitive strains. Clinical implementation of our rapid SYBR-MAMAs will permit timely treatment alterations to improve patient outcomes.

35 The ESKAPE pathogen, *P. aeruginosa*, has a remarkable capacity to develop AMR towards all
36 clinically-relevant antibiotic classes (1). This bacterium can cause life-threatening infections,
37 particularly in people with wounds, cancer, or chronic respiratory diseases such as cystic fibrosis (CF)
38 or chronic obstructive pulmonary disease (COPD) (2).

39 Rapid, affordable, accessible, and accurate AMR diagnosis is crucial in the battle against ESKAPE
40 pathogens (1). However, few diagnostic tests exist (3) for rapidly and inexpensively characterising
41 AMR-conferring single-nucleotide polymorphisms (SNPs) in *P. aeruginosa*, a striking knowledge gap
42 given that SNPs confer AMR towards anti-pseudomonal drugs such as fluoroquinolones (FQs) (4).

43 FQs (predominantly ciprofloxacin [CIP]) have proven clinically useful for treating *P. aeruginosa*
44 infections (5). Yet, upon exposure, *P. aeruginosa* often develops FQ resistance (FQr). Codon-altering
45 mutations within the GyrA quinolone-resistance-determining region (QRDR) can confer an
46 intermediate (CIPi) or fully resistant (CIPr) CIP phenotype (6, 7); in contrast, *gyrB*, *parC*, *parE* and
47 *nfxB* typically require ≥2 mutations to impart CIPi/CIPr (8).

48 Due to the single-step nature of QRDR mutations in conferring CIPi/CIPr, and their prevalence in
49 clinical isolates (9), we targeted the two most common QRDR SNPs, *gyrA*248 (4) and *gyrA*259 (10),
50 for assay development. We chose SYBR Green-based mismatch amplification mutation assay (SYBR-
51 MAMA), an inexpensive (~AUD$2/assay), simple, rapid (~1h turnaround time) and scalable method
52 (11-15) that exploits the differential efficiency of allele-specific amplification for SNP interrogation;
53 this efficiency disparity can be observed in real-time by measuring the difference in cycles-to-
54 threshold (ΔC_T) (12, 14, 15).

55 Eighty-four *P. aeruginosa* isolates from Southeast Queensland, Australia, were examined: 46 from
56 sputum (CF adults with chronic *P. aeruginosa* infection [*n*=42] (16); COPD [*n*=3] (16); non-CF
57 bronchiectasis [*n*=1]), 35 from bloodstream infections occurring between 2008 and 2011 (17), and 3
58 from other specimen types, collected between 2017 and 2021 (Table 1). PAO1 was included as a
59 wild-type control. Sample collection and analysis was approved by The Prince Charles Hospital

60 Human Research Ethics Committee or the Royal Brisbane and Women's Hospital Institutional Review
61 Board. All CF and COPD participants provided written consent (16). A waiver of informed consent
62 was approved for other sample types due to a low-to-negligible risk assessment (17, 18).

63 Strains were isolated using MacConkey agar (Oxoid, VIC, Australia) incubated at 37°C for 24h and
64 confirmed as *P. aeruginosa* by *ecfX* real-time PCR (19). Susceptibility towards CIP [5µg], levofloxacin
65 (LEV; 5 µg), moxifloxacin (MFX; 5 µg), and ofloxacin (OFX; 5 µg) was determined by disc diffusion
66 (Edwards Group, QLD, Australia) using CLSI M100S-Ed27:2017 guidelines (Table 2).

67 Isolates were DNA-extracted using the DNeasy kit (Qiagen, Chadstone Centre, VIC, Australia),
68 followed by Illumina paired-end whole-genome sequencing (WGS) (18). Quality-filtered reads (20)
69 were assembled with MGAP v1.1 (https://github.com/dsarov/MGAP---Microbial-Genome-
70 Assembler-Pipeline) or SPAdes (21). AMR prediction was undertaken using a *P. aeruginosa*-specific
71 ARDaP (22) database. Assemblies were deposited into the PubMLST database
72 (https://pubmlst.org/organisms/pseudomonas-aeruginosa). Illumina data are available via
73 BioProject PRJNA761496.

74 SYBR-MAMA primers were assessed *in silico* for dimer formation and specificity as described
75 previously (23). For the *gyrA*248 SYBR-MAMA, gyrA248_T_AMR amplifies the CIPi/CIPr-conferring
76 T83I allele, whereas gyrA248_C_WT amplifies the wild-type allele (Table 3). For the *gyrA*259 SYBR-
77 MAMA, gyrA259_D_AMR amplifies mutant alleles at position 259 (D87N, D87Y, D87H), all of which
78 confer CIPi/CIPr (4, 8), whereas gyrA259_G_WT amplifies the wild-type allele (10). PCRs consisted of
79 1× SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, NSW, Australia), 0.2µM primers, 1µL
80 template, and PCR-grade H_2O, to 5µL. Thermocycling comprised 95°C for 2min, followed by 40 cycles
81 of 95°C for 5s and 60°C for 5sec. Strains used to validate *gyrA* 248 and 259 alleles are listed in Table
82 2. Following validation, SYBR-MAMAs were screened across the 85 genome-sequenced *P.*
83 *aeruginosa* isolates, comprising 40 CIP-sensitive (including PAO1), 29 CIPi, and 16 CIPr strains (Table
84 1). Of these, only one, SCHI0050.S.1, was derived from a participant receiving FQ (CIP) treatment,

85 and this isolate was CIP-sensitive (Table 1). Unexpectedly, none of the 45 CIPi/CIPr strains were from
86 participants known to be receiving contemporaneous FQ antibiotics (Table 1), although we did not
87 investigate recent FQ exposure.

88 The *gyrA*248 SYBR-MAMA robustly discriminated GyrA T83I from wild-type strains, with matched
89 alleles consistently amplifying earlier than mismatched counterparts (T83I ΔC_T=4.0±0.03 vs. wild-
90 type ΔC_T=7.6±0.1 [Figures 1A and 1B]). Four tested GyrA T83I strains also demonstrated
91 intermediate or full resistance towards LEV, MFX, and OFX (Table 2), confirming the importance of
92 this variant in broader FQr. T83I is considered the most common GyrA variant in CIPi/CIPr strains (4,
93 9, 24); for example, two Japanese studies reported 82% (60/73) (25) and 75% (112/150) (26) T83I
94 prevalence among CIPi/CIPr isolates, and a Vietnamese study reported 54% (76/141) prevalence (9).
95 In our dataset, T83I was detected in 29% (13/45) CIPi/CIPr strains and 0% (0/40) CIP-sensitive strains
96 (Table 1), suggesting that T83I is an important, but not dominant, cause of CIPi/CIPr in Australian
97 isolates, although testing across a broader isolate collection is required to confirm this observation.

98 Like *gyrA*248, there was clear discrimination between AMR and wild-type genotypes for the *gyrA*259
99 SYBR-MAMA, with AMR alleles amplifying earlier in AMR-encoding strains (D87Y ΔC_T=14.7 [Figure
100 2A]; D87N ΔC_T=9.6±0.04 [Figure 2B]; D87H ΔC_T=13.5±0.2 [Figure 2C]), and vice versa for wild-type
101 strains (ΔC_T=10.8; Figure 2D). *gyrA*259 AMR was detected in 56% (25/45) CIPi/CIPr and 0% (0/40)
102 CIP-sensitive strains. D87H was most common according to WGS, accounting for 88% (22/25)
103 *gyrA*259 AMR strains (Table 1).

104 Like T83I, seven tested strains encoding D87Y, D87N and D87H all exhibited intermediate or full LEV,
105 MFX, and OFX resistance (Table 2). The *gyrA* mutations had a larger impact on MFX and OFX (causing
106 AMR) compared with CIP and LEV (causing intermediate resistance) (Table 2). This observation
107 supports the hypothesis that additional mutation/s are sometimes required to confer AMR towards
108 CIP and LEV (10).

109 In conclusion, we found that the *gyrA*248 and *gyrA*259 SYBR-MAMAs detected FQ non-susceptibility
110 in 84% Australian CIPi/CIPr strains. Of the remaining strains, three encoded missense mutations at
111 GyrB466 with or without other FQr-conferring mutations (ParE Ala473Val, MexR Gln25Stop),
112 whereas four had no known FQr determinants (Table 1). A possible explanation for these latter
113 strains is phenotype misclassification as 3/4 strains sat on the CIPi/sensitivity breakpoint. All FQ-
114 sensitive strains yielded wild-type genotypes for both assays, demonstrating 100% specificity. Our
115 two *gyrA* SYBR-MAMAs thus provide a same-day, inexpensive, simple, and accurate tool for
116 detecting the most prevalent causes of FQ non-susceptibility in *P. aeruginosa*.

Acknowledgements

We thank Patrick Harris at UQ Centre for Clinical Research for helpful discussions. This work was supported by Advance Queensland (awards AQIRF0362018 and AQRF13016-17RD2), an Australian Government Research Training Program Scholarship, the Wishlist Sunshine Coast Health Foundation (award 2019-14), and the National Health and Medical Research Council (award 455919). The funders had no role in study design, data acquisition, analysis, interpretation, writing or submission of the manuscript.

124 **Tables**

125 **Table 1. *Pseudomonas aeruginosa* isolates used in this study, and their DNA gyrase A (GyrA) SYBR-MAMA PCR genotypes, whole-genome sequencing**

126 **(WGS) results, multilocus sequence types, and treatment details**

Strain	Disease	*gyrA*248 allele (PCR)	*gyrA*259 allele (PCR)	GyrA AMR mutation (WGS)	Other CIP AMR-conferring mutations (WGS)	Sequence Type	Treatment at time of collection
CIP-resistant							
SCHI0004.S.5	CF	AMR	WT	T83I	None	ST649	Day 14 IV MEM, TOB
SCHI0008.S.3	CF	AMR	WT	T83I	None	ST649	Day 8 IV ATM, DOX
SCHI0010.S.1	CF	AMR	WT	T83I	None	ST4	Day 7 IV CAZ, TOB
SCHI0016.S.124	UTI	WT	AMR	D87N	MexR (Ile24fs; loss; upregulates MexAB efflux pump)	ST309	Unknown
SCHI0021.S.7	CF	WT	AMR	D87H	None	ST801	Day 13 IV CAZ, TOB
SCHI0025.S.15	CF	WT	AMR	D87H	None	ST801	Unknown
SCHI0027.S.1	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0029.S.1	CF	WT	AMR	D87H	None	ST801	Day 1 unknown antibiotic/s
SCHI0030.S.4	CF	WT	AMR	D87H	None	ST801	None
SCHI0032.S.32	Ulcer	WT	AMR	D87N	None	ST143#	Unknown
SCHI0032.S.33	Ear infection	WT	AMR	D87Y	None	ST848^	Unknown
SCHI0033.S.2	BSI	AMR	WT	T83I	ParE (Ala473Val), NalD (Met1del; upregulates MexAB efflux pump)	ST847	Unknown

SCHI0033.S.4	BSI	AMR	WT	T83I	None	ST244	Unknown
SCHI0033.S.15	BSI	AMR	WT	T83I	ParC (Ser87Leu)	ST532	Unknown
SCHI0033.S.19	BSI	AMR	WT	T83I	ParC (Ser87Leu)	ST235	Unknown
SCHI0033.S.26	BSI	WT	WT	None	None	ST147	Unknown
CIP-intermediate							
SCHI0002.S.8	CF	WT	WT	None	GyrB (Ser466Phe)	ST4	Day 7 IV CAZ, MEM, TOB
SCHI0002.S.9	CF	WT	WT	None	None	ST683	Day 7 IV CAZ, MEM, TOB
SCHI0002.S.12	CF	WT	WT	None	None	ST683	Day 37 IV CAZ, MEM, TOB
SCHI0003.S.1	CF	AMR	WT	T83I	None	ST649	Day 4 IV ATM, MEM, TOB
SCHI0003.S.3	CF	AMR	WT	T83I	None	ST649	Day 4 IV ATM, MEM, TOB
SCHI0003.S.8	CF	WT	AMR	D87H	None	ST801	Day 4 IV ATM, MEM, TOB
SCHI0005.S.9	CF	WT	AMR	D87H	None	ST801	Day 10 IV MEM, TOB
SCHI0005.S.10	CF	WT	AMR	D87H	None	ST801	Day 10 IV MEM, TOB
SCHI0005.S.11	CF	WT	AMR	D87H	None	ST801	Day 10 IV MEM, TOB
SCHI0006.S.10	CF	WT	AMR	D87H	None	ST801	None
SCHI0008.S.2	CF	AMR	WT	T83I	None	ST649	Day 8 IV ATM, DOX
SCHI0008.S.4	CF	AMR	WT	T83I	None	ST649	Day 8 IV ATM, DOX
SCHI0013.S.12	CF	WT	WT	None	GyrB (Ser466Tyr), ParE (Ala473Val)	ST775	Day 4 FOF, MEM
SCHI0016.S.57	BE	WT	WT	None	GyrB (Ser466Phe), MexR (Gln25stop; upregulates MexAB efflux pump)	ST2601	>2 weeks MEM, GEN, CRO, FEP
SCHI0021.S.5	CF	WT	AMR	D87H	None	ST801	Day 5 IV CAZ, TOB

SCHI0021.S.6	CF	WT	AMR	D87H	None	ST801	Day 5 IV CAZ, TOB
SCHI0021.S.8	CF	WT	AMR	D87H	None	ST801	Day 13 IV CAZ, TOB
SCHI0021.S.10	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0021.S.11	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0021.S.12	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0021.S.14	CF	WT	AMR	D87H	None	ST801	None
SCHI0025.S.9	CF	AMR	WT	T83I	None	ST649	Unknown
SCHI0027.S.2	CF	WT	AMR	D87H	None	ST801	Day 12 IV CAZ, TOB
SCHI0027.S.3	CF	WT	AMR	D87H	None	ST801	Day 9 IV CAZ, TOB
SCHI0027.S.5	CF	WT	AMR	D87H	None	ST801	None
SCHI0030.S.2	CF	WT	AMR	D87H	None	ST801	Day 6 IV ATM, TOB
SCHI0030.S.3	CF	WT	AMR	D87H	None	ST801	Day 13 IV ATM, TOB
SCHI0033.S.14	BSI	WT	WT	None	None	ST571	Unknown
SCHI0033.S.29	BSI	AMR	WT	T83I	None	ST244	Unknown
CIP-sensitive							
SCHI0005.S.8	CF	WT	WT	None	ParE (Ala473Val), AmgS (Val121Gly; upregulates MexXY efflux pump)	ST262	Day 10 IV MEM, TOB
SCHI0013.S.2	CF	WT	WT	None	GyrB (Ser466Tyr), ParE (Ala473Val)	ST775	Day 4 FOF, MEM
SCHI0020.S.4	CF	WT	WT	None	ParE (Ala473Val), NfxB (large deletion, upregulates MexCD efflux pump)	ST3828*	Day 1 IV CAZ, TOB
SCHI0020.S.5	CF	WT	WT	None	ParE (Ala473Val), NfxB (large deletion, upregulates MexCD efflux pump)	ST3828*	None

SCHI0020.S.6	CF	WT	WT	None	ParE (Ala473Val), NfxB (loss, upregulates MexCD efflux pump)	ST3828*	Day 1 IV CAZ, TOB
SCHI0027.S.4	CF	WT	WT	None	None	ST801	None
SCHI0030.S.1	CF	WT	WT	None	None	ST275	None
SCHI0030.S.5	CF	WT	WT	None	None	ST275	None
SCHI0033.S.1	BSI	WT	WT	None	None	ST3864*	Unknown
SCHI0033.S.3	BSI	WT	WT	None	None	ST3829	Unknown
SCHI0033.S.5	BSI	WT	WT	None	None	ST274	Unknown
SCHI0033.S.7	BSI	WT	WT	None	None	ST252	Unknown
SCHI0033.S.8	BSI	WT	WT	None	None	ST649	Unknown
SCHI0033.S.9	BSI	WT	WT	None	None	ST708	Unknown
SCHI0033.S.10	BSI	WT	WT	None	None	ST244	Unknown
SCHI0033.S.11	BSI	WT	WT	None	None	ST3865*	Unknown
SCHI0033.S.12	BSI	WT	WT	None	None	ST865	Unknown
SCHI0033.S.13A	BSI	WT	WT	None	None	ST395	Unknown
SCHI0033.S.13B	BSI	WT	WT	None	None	ST395	Unknown
SCHI0033.S.16	BSI	WT	WT	None	NfxB (Phe126fs; upregulates MexCD efflux pump)	ST909	Unknown
SCHI0033.S.17	BSI	WT	WT	None	None	ST274	Unknown
SCHI0033.S.18	BSI	WT	WT	None	None	ST348	Unknown
SCHI0033.S.20	BSI	WT	WT	None	None	ST274	Unknown
SCHI0033.S.23	BSI	WT	WT	None	None	ST3843*	Unknown
SCHI0033.S.24	BSI	WT	WT	None	None	ST471	Unknown
SCHI0033.S.25	BSI	WT	WT	None	None	ST815	Unknown
SCHI0033.S.27	BSI	WT	WT	None	None	ST395	Unknown

SCHI0033.S.28	BSI	WT	WT	None	None	ST3804	Unknown
SCHI0033.S.30	BSI	WT	WT	None	None	ST782	Unknown
SCHI0033.S.32	BSI	WT	WT	None	None	ST298	Unknown
SCHI0033.S.33	BSI	WT	WT	None	MexR (Arg91fs; upregulates MexAB efflux pump	ST17	Unknown
SCHI0033.S.35	BSI	WT	WT	None	None	ST348	Unknown
SCHI0033.S.36	BSI	WT	WT	None	None	ST3830*	Unknown
SCHI0033.S.37	BSI	WT	WT	None	CrpP (gene gain)	ST298	Unknown
SCHI0033.S.38	BSI	WT	WT	None	None	ST235	Unknown
SCHI0033.S.39	BSI	WT	WT	None	None	ST1189	Unknown
SCHI0038.S.3	COPD	WT	WT	None	None	ST888	None
SCHI0039.S.1	COPD	WT	WT	None	None	ST3134	None
SCHI0050.S.1	COPD	WT	WT	None	ParC (Gln405Arg)	ST3323	Day 3 oral CIP
PAO1	Wound	WT	WT	None	None	ST549	Unknown

127 Abbreviations: AMR, antimicrobial-resistant; ATM, aztreonam; BE, bronchiectasis; BSI, bloodstream infection, CAZ, ceftazidime; CF, cystic fibrosis; CIP,

128 ciprofloxacin; COPD, chronic obstructive pulmonary disease; CRO, ceftriaxone; DOX, doxycycline; FEP, cefepime; FOF, fosfomycin; GEN, gentamicin; IV,

129 intravenous; MEM, meropenem; SYBR-MAMA, SYBR Green-based mismatch amplification mutation assay; TOB, tobramycin; UTI, urogenital tract infection;

130 WGS, whole-genome sequencing; WT, wild-type

131 *Novel multilocus sequence type (ST) identified in this study

132 #SCHI0032.S.32 submitted to PubMLST under isolate name AUS205 (ID:1023) (27)

133 ^SCHI0032.S.33 submitted to PubMLST under the isolate name AUS134 (ID:952) (27)

134 **Table 2. *Pseudomonas aeruginosa* isolates used for *gyrA*248 and *gyrA*259 SYBR-MAMA assay**

135 **validation, and associated fluoroquinolone-class antibiotic disc diffusion data**

gyrA phenotype	Isolate ID	CIP	LEV	OFX	MFX	WT to AMR (codon change)
AMR (mutant)	SCHI0003.S.3	I	I	R	R	*gyrA*248 T→C (T83I)
	SCHI0008.S.4	R	I	R	R	
	SCHI0010.S.1	R	R	R	R	
	SCHI0025.S.9	R	R	R	R	
	SCHI0016.S.124	R	R	R	R	*gyrA*259 G→A (D87N)
	SCHI0032.S.32	I	R	R	R	
	SCHI0003.S.8	I	I	R	R	*gyrA*259 G→C (D87H)
	SCHI0005.S.10	R	I	I	R	
	SCHI0025.S.15	R	R	R	R	
	SCHI0029.S.1	R	R	R	R	
	SCHI0032.S.33	I	I	R	R	*gyrA*259 G→T (D87Y)
WT (control)	SCHI0038.S.3	S	S	S	S	No mutation at *gyrA*248 or *gyrA*259
	SCHI0039.S.1	S	S	S	S	
	SCHI0050.S.1	S	S	S	S	
	SCHI0032.S.22 (PAO1)	S	S	S	S	

136 Abbreviations: AMR, antimicrobial-resistant; CIP, ciprofloxacin; I, intermediate; LEV, levofloxacin;

137 MFX, moxifloxacin; OFX, ofloxacin; R, resistant; S, sensitive; WT, wild-type.

138 **Table 3. SYBR Green-based mismatch amplification mutation assay (SYBR-MAMA) primers**

139 **designed in this study**

***gyrA* SNP**	GyrA AMR variant	Primer name	Sequence (5'-3')*	Optimised concentration (µM)
***gyrA*248**	T83I	gyrA248_T_AMR	ACGATGGTGTCGTAGACCG<u>t</u>G**a**	0.30
		gyrA248_C_WT	CGATGGTGTCGTAGACCG<u>t</u>G**g**	0.30
		gyrA248_F	TGTGGTCGGCGACGTGATC	0.20
***gyrA*259**	D87N, D87Y, D87H	gyrA259_D_AMR	CATGCGCACGATGGTG<u>a</u>**d**	0.20
		gyrA259_G_WT	GCCATaCGCACGATGGTG<u>a</u>**c**	0.20
		gyrA259_F	AGCTGGGCAACGACTGGAA	0.20

140 Abbreviations: AMR, antimicrobial resistant (allele); SNP, single-nucleotide polymorphism; WT, wild-

141 type (allele)

142 *Bolded nucleotides indicate the SNP; underlined nucleotides indicate deliberately incorporated

143 antepenultimate/penultimate mismatches to enhance allele specificity

144 **Figure legends**

145 **Figure 1.** SYBR Green-based mismatch amplification mutation assay (SYBR-MAMA) interrogation of
146 the *gyrA*248 (T→C) biallelic single-nucleotide polymorphism, resulting in a threonine to isoleucine
147 substitution at position 83 (T83I) in certain fluoroquinolone (FQ)-resistant *P. aeruginosa* isolates.
148 *gyrA*248 SYBR-MAMA performance in: **A**. SCHI0010.S.1 (FQ-resistant, encodes T83I); **B.** SCHI0038.S.1
149 (FQ-sensitive wild-type isolate). Orange, antimicrobial-resistant allele; blue, wild-type allele. No-
150 template controls did not amplify.

151 **Figure 2**. SYBR Green-based mismatch amplification mutation assay (SYBR-MAMA) interrogation of
152 the *gyrA*259 (G→A/C/T) tetra-allelic single-nucleotide polymorphism, resulting in aspartate to
153 asparagine (D87N), histidine (D87H), or tyrosine (D87Y) substitutions, respectively, at position 87 in
154 certain fluoroquinolone (FQ)-resistant *Pseudomonas aeruginosa* isolates. *gyrA*259 SYBR-MAMA
155 performance in: **A.** SCHI0005.S.10 (FQ-resistant, encodes D87H); **B.** SCHI0033.S.32 (FQ-resistant,
156 encodes D87N); **C.** SCHI0033.S.33 (FQ-resistant, encodes D87Y); and **D.** SCHI0038.S.3 (FQ-sensitive
157 wild-type isolate). Purple, antimicrobial-resistant allele; aqua, wild-type allele. No-template controls
158 did not amplify.

159 **References**

160 1. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. *Pseudomonas aeruginosa*: all
161 roads lead to resistance. *Trends Microbiol* 19:419-426.
162 2. Botelho J, Grosso F, Peixe L. 2019. Antibiotic resistance in *Pseudomonas aeruginosa* -
163 mechanisms, epidemiology and evolution. *Drug Resist Updat* 44:100640.
164 3. Schwartz T, Volkmann H, Kirchen S, Kohnen W, Schon-Holz K, Jansen B, Obst U. 2006. Real-
165 time PCR detection of *Pseudomonas aeruginosa* in clinical and municipal wastewater and
166 genotyping of the ciprofloxacin-resistant isolates. *FEMS Microbiol Ecol* 57:158-67.
167 4. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. 2003. Mutations in GyrA, ParC, MexR
168 and NfxB in clinical isolates of Pseudomonas aeruginosa. *Int J Antimicrob Agents* 21:409-13.
169 5. Poole K. 2011. *Pseudomonas aeruginosa*: resistance to the max. *Front Microbiol* 2:65-65.
170 6. Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of
171 topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-
172 resistant clinical isolates of Pseudomonas aeruginosa. *Int J Antimicrob Agents* 25:290-5.
173 7. Yonezawa M, Takahata M, Matsubara N, Watanabe Y, Narita H. 1995. DNA gyrase *gyrA*
174 mutations in quinolone-resistant clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob*
175 *Agents Chemother* 39:1970-1972.
176 8. Rehman A, Jeukens J, Levesque RC, Lamont IL. 2021. Gene-gene interactions dictate
177 ciprofloxacin resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance
178 phenotype from genome sequence data. *Antimicrob Agents Chemother* 65:e0269620.
179 9. Nguyen KV, Nguyen TV, Nguyen HTT, Le DV. 2018. Mutations in the gyrA, parC, and mexR
180 genes provide functional insights into the fluoroquinolone-resistant Pseudomonas
181 aeruginosa isolated in Vietnam. *Infect Drug Resist* 11:275-282.
182 10. Rehman A, Patrick WM, Lamont IL. 2019. Mechanisms of ciprofloxacin resistance in
183 Pseudomonas aeruginosa: new approaches to an old problem. *J Med Microbiol* 68:1-10.
184 11. Birdsell DN, Pearson T, Price EP, Hornstra HM, Nera RD, Stone N, Gruendike J, Kaufman EL,
185 Pettus AH, Hurbon AN, Buchhagen JL, Harms NJ, Chanturia G, Gyuranecz M, Wagner DM,
186 Keim PS. 2012. Melt analysis of mismatch amplification mutation assays (Melt-MAMA): a
187 functional study of a cost-effective SNP genotyping assay in bacterial models. *PLoS One*
188 7:e32866.
189 12. Germer S, Higuchi R. 1999. Single-tube genotyping without oligonucleotide probes. *Genome*
190 *Res* 9:72-8.
191 13. Donà V, Smid JH, Kasraian S, Egli-Gany D, Dost F, Imeri F, Unemo M, Low N, Endimiani A.
192 2018. Mismatch amplification mutation assay-based real-time PCR for rapid detection of
193 *Neisseria gonorrhoeae* and antimicrobial resistance determinants in clinical specimens. *J Clin*
194 *Microbiol* 56:e00365-18.
195 14. Sarovich DS, Price EP, Von Schulze AT, Cook JM, Mayo M, Watson LM, Richardson L,
196 Seymour ML, Tuanyok A, Engelthaler DM, Pearson T, Peacock SJ, Currie BJ, Keim P, Wagner
197 DM. 2012. Characterization of ceftazidime resistance mechanisms in clinical isolates of
198 Burkholderia pseudomallei from Australia. *PLoS One* 7:e30789.
199 15. Germer S, Holland MJ, Higuchi R. 2000. High-throughput SNP allele-frequency determination
200 in pooled DNA samples by kinetic PCR. *Genome Res* 10:258-66.
201 16. Webb KA, Olagoke O, Baird T, Neill J, Pham A, Wells TJ, Ramsay KA, Bell SC, Sarovich DS,
202 Price EP. 2021. Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated
203 from chronic lung disease airways. *MedRxiv*
204 doi:https://doi.org/10.1101/2021.08.30.21262864.
205 17. McCarthy KL, Paterson DL. 2017. Long-term mortality following *Pseudomonas aeruginosa*
206 bloodstream infection. *J Hosp Infect* 95:292-299.
207 18. Stewart AG, Price EP, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich
208 DS. 2021. Molecular epidemiology of third-generation-cephalosporin-resistant

209 Enterobacteriaceae in Southeast Queensland, Australia. *Antimicrob Agents Chemother*
210 65:e00130-21.
211 19. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP. 2009.
212 Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction
213 assay targeting the *ecfX* and the *gyrB* genes. *Diagn Microbiol Infect Dis* 63:127-131.
214 20. Price EP, Viberg LT, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. 2018. Transcriptomic analysis of
215 longitudinal *Burkholderia pseudomallei* infecting the cystic fibrosis lung. *Microb Genom*
216 4:e000194.
217 21. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI,
218 Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner
219 PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell
220 sequencing. *J Comput Biol* 19:455-477.
221 22. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS. 2021. Taking the next-gen
222 step: comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*.
223 *EBioMedicine* 63:103152.
224 23. Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen T-K, Kidd TJ, Nimmo GR, Sarovich
225 DS, Price EP. 2019. Quantitative real-time PCR assay for the rapid identification of the
226 intrinsically multidrug-resistant bacterial pathogen *Stenotrophomonas maltophilia*. *Microb*
227 *Genom* 5:e000307.
228 24. Farahi RM, Ali AA, Gharavi S. 2018. Characterization of gyrA and parC mutations in
229 ciprofloxacin-resistant Pseudomonas aeruginosa isolates from Tehran hospitals in Iran. *Iran J*
230 *Microbiol* 10:242-249.
231 25. Takenouchi T, Sakagawa E, Sugawara M. 1999. Detection of gyrA mutations among 335
232 *Pseudomonas aeruginosa* strains isolated in Japan and their susceptibilities to
233 fluoroquinolones. *Antimicrob Agents Chemother* 43:406-9.
234 26. Akasaka T, Tanaka M, Yamaguchi A, Sato K. 2001. Type II topoisomerase mutations in
235 fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and
236 1999: role of target enzyme in mechanism of fluoroquinolone resistance. *Antimicrob Agents*
237 *Chemother* 45:2263-8.
238 27. Kidd TJ, Ritchie SR, Ramsay KA, Grimwood K, Bell SC, Rainey PB. 2012. *Pseudomonas*
239 *aeruginosa* exhibits frequent recombination, but only a limited association between
240 genotype and ecological setting. *PLoS One* 7:e44199.

241


A.
Amplification
RFU
10^4
10^2
0
10
20
30
40
Cycles


B.
Amplification
RFU
10^4
10^2
0
10
20
30
40
Cycles


A.
Amplification
RFU
10^4
10^2
0
10
20
30
40
Cycles
B.
Amplification
RFU
10^4
10^2
0
10
20
30
40
Cycles
C.
Amplification
RFU
10^2
0
10
20
30
40
Cycles
D.
Amplification
RFU
10^5
10^4
10^3
10^2
0
10
20
30
40
Cycles